<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742326</url>
  </required_header>
  <id_info>
    <org_study_id>080201</org_study_id>
    <nct_id>NCT00742326</nct_id>
  </id_info>
  <brief_title>Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections</brief_title>
  <official_title>Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of pioglitazone in reducing liver fat content in&#xD;
      patients with HIV and hepatitis C virus (HCV) infections. Fatty liver and accompanying&#xD;
      insulin resistance in patients with HIV and HCV co-infections is associated with inflammatory&#xD;
      changes, liver fibrosis and a poorer response to HCV treatment. Pioglitazone is a drug that&#xD;
      helps to reduce the body's resistance to insulin. It is approved by the Food and Drug&#xD;
      Administration to treat diabetes.&#xD;
&#xD;
      Patients with HIV and HCV co-infections who have hepatic steatosis (fatty liver) may be&#xD;
      eligible for this study. Candidates are screened with a medical history and physical&#xD;
      examination, blood and urine tests, magnetic resonance imaging (MRI) of the liver to measure&#xD;
      liver fat and, if needed, a liver biopsy to confirm the diagnosis of liver steatosis.&#xD;
&#xD;
        -  Participants are randomly assigned to take either pioglitazone therapy or placebo for 48&#xD;
           weeks. This is followed by a second 48-week treatment period in which all participants&#xD;
           take pioglitazone.&#xD;
&#xD;
        -  There are approximately 12 visits during the 96 weeks of the study. Participants will&#xD;
           receive a physical assessment, blood and urine tests at each visit. In addition,&#xD;
           periodic assessments of dietary habits, body composition, oral glucose tolerance&#xD;
           testing, and health related quality of life questionnaires will be completed.&#xD;
&#xD;
        -  A repeat MRI of the liver is performed at 48 weeks and at the end of the study to&#xD;
           evaluate any potential changes in liver fat and inflammation. In addition, there is a&#xD;
           follow-up liver biopsy at 48 weeks and an optional liver biopsy at 96 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following the introduction of effective antiretroviral therapy for HIV, the management of&#xD;
      co-morbidities such as hepatitis C virus (HCV) has taken on increasing significance in the&#xD;
      care and health maintenance of chronically infected patients. HCV co-infection is common in&#xD;
      HIV, with an estimated prevalence of 30 percent among HIV-infected adults in the US. Further,&#xD;
      the reported prevalence of hepatic steatosis in HIV/HCV co-infection is between 40-67&#xD;
      percent.&#xD;
&#xD;
      In recent years, the significance of hepatic steatosis and accompanying insulin resistance in&#xD;
      HCV has gained increasing recognition. For example, steatosis is associated with increased&#xD;
      rates of necro-inflammatory change and fibrosis in HIV/HCV co-infected patients. Furthermore,&#xD;
      studies showed that, among non-HIV infected HCV patients, the presence of steatosis and/or&#xD;
      insulin resistance was associated with poorer response to HCV therapy. These observations&#xD;
      have led to research interest in treating hepatic steatosis in HCV, particularly in the&#xD;
      context of pegylated interferon and ribavirin therapy.&#xD;
&#xD;
      Administration of the thiazolidinedione, pioglitazone, leads to significant reductions in&#xD;
      hepatic steatosis, inflammation and in some cases fibrosis in patients with non-alcoholic&#xD;
      steatohepatitis (NASH). Therefore, the potential benefits of pioglitazone therapy in the&#xD;
      setting of HIV/HCV co-infection and hepatic steatosis will be determined. The proposed study&#xD;
      is a 48-week, double-blind, randomized placebo-controlled trial of pioglitazone (45 mg/day)&#xD;
      in 50 HIV/HCV-infected men and women. After the 48-week randomized portion of the trial, all&#xD;
      participants will enter a 48-week open treatment extension arm irrespective of original&#xD;
      randomization. It is anticipated that 100 subjects will be needed to be screened to identify&#xD;
      a sufficient number of eligible participants to enroll in the study.&#xD;
&#xD;
      The primary outcome variable of interest in this trial will be the change in hepatic fat&#xD;
      content measured by magnetic resonance (MR) spectroscopy. Important secondary outcomes will&#xD;
      be histologic improvement on liver biopsy performed at baseline and 48 weeks, as well as&#xD;
      improvements in transaminase levels and insulin resistance. The open treatment extension will&#xD;
      allow all participants an opportunity to receive active study medication and it will allow&#xD;
      the potential benefits of additional pioglitazone therapy to be assessed. In this way,&#xD;
      important information about the efficacy of pioglitazone to treat hepatic steatosis and&#xD;
      improve the metabolic profile in HIV/HCV co-infected patients will be obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment stopped prior to complete enrollment due to slow accrual&#xD;
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <condition>Liver Disease</condition>
  <condition>Fatty Liver</condition>
  <condition>Steatosis</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pioglitazone 45 mg daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one capsule daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>45 mg/daily</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one capsule daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Men and women, 18 years of age or greater&#xD;
&#xD;
        Confirmed HIV infection by ELISA and Western blot&#xD;
&#xD;
        No changes in antiretroviral regimen within the prior 3 months--Individuals not currently&#xD;
        taking antiretroviral therapy will be eligible. Individuals requiring medically indicated&#xD;
        adjustments of antiretroviral therapy during the course of the study will be eligible.&#xD;
&#xD;
        Confirmed HCV infection, and no current or recent (within the past 3 months) HCV treatment&#xD;
        and no plans to start HCV antiviral therapy in the foreseeable future.&#xD;
&#xD;
        H-MRS liver fat content greater than 5 percent and confirmed steatosis on liver biopsy&#xD;
        within 1 year&#xD;
&#xD;
        Fasting glucose less than 126 mg/dL&#xD;
&#xD;
        Platelets greater than or equal to 75,000/uL; INR less than 1.6&#xD;
&#xD;
        Willingness to avoid medications and herbal supplements which may increase the risk of&#xD;
        bleeding for one week prior to and one week following liver biopsy (e.g. aspirin,&#xD;
        nonsteroidal anti-inflammatory drugs (NSAIDs), Vitamin E, fish oil and gingko biloba).&#xD;
&#xD;
        Willingness to restrict physical activity 72 hours after liver biopsy&#xD;
&#xD;
        If premenopausal female, willingness to use 2 forms of effective birth control on this&#xD;
        study to avoid pregnancy.&#xD;
&#xD;
        Have a primary care physician&#xD;
&#xD;
        Willingness to have specimens stored.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Current thiazolidinedione use or use in the last 6 months, known allergy or sensitivity to&#xD;
        a thiazolidinedione&#xD;
&#xD;
        Use of insulin or other oral hypoglycemics, or known diabetes&#xD;
&#xD;
        Current pregnancy, breast feeding, or pregnancy within the past 6 months or desire to&#xD;
        become pregnant within the next 2 years.&#xD;
&#xD;
        Child-Pugh-Turcotte (CPT) score greater than class A&#xD;
&#xD;
        ALT greater than 4 times the upper limit of normal&#xD;
&#xD;
        Current or history of heart failure (New York Heart Association [NYHA] Class III or IV&#xD;
        cardiac status)&#xD;
&#xD;
        Hemoglobin level less than 9g/dL&#xD;
&#xD;
        Active or ongoing infection with Hepatitis A or B&#xD;
&#xD;
        Known or suspected liver disease such as autoimmune hepatitis, Wilson's disease,&#xD;
        alpha-1-antitrypsin deficiency, cystic fibrosis, hemochromatosis, glycogen storage disease,&#xD;
        amyloidosis, primary biliary cirrhosis, sclerosing cholangitis, or any primary or secondary&#xD;
        hepatic tumor&#xD;
&#xD;
        Current alcohol/substance abuse&#xD;
&#xD;
        Use of growth hormone, prednisone or other anabolic agents (except for physiologic&#xD;
        testosterone replacement) currently or within the past 3 months. One day or less of&#xD;
        corticosteroid within the prior 90 days of screening is allowed as is stable dose&#xD;
        inhalation corticosteroids&#xD;
&#xD;
        Concurrent use of ketoconazole&#xD;
&#xD;
        Active opportunistic infection (except thrush) or neoplasm (except Kaposi's sarcoma, skin&#xD;
        cancer, cancer of the cervix or anus)&#xD;
&#xD;
        Any known contraindications to percutaneous liver biopsy including elevated PT/PTT&#xD;
&#xD;
        Severe psychiatric illness that would interfere with adherence to protocol requirements&#xD;
&#xD;
        Current treatment with interleukin-2, interferon-alpha, or other investigational agent(s)&#xD;
        within the past 6 months (This does not pertain to ARVs obtained through expanded access)&#xD;
&#xD;
        Any significant medical condition for which the investigator believes a liver biopsy or&#xD;
        participation in the research protocol may be contraindicated&#xD;
&#xD;
        Any contraindication to MRI scan, including excess body size&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen M Hadigan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis. 2003 Apr 15;36(8):1030-8. Epub 2003 Apr 2.</citation>
    <PMID>12684916</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000 Apr;30 Suppl 1:S77-84. Review.</citation>
    <PMID>10770916</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005 Mar 24;19(6):585-92.</citation>
    <PMID>15802977</PMID>
  </reference>
  <reference>
    <citation>Matthews L, Kleiner DE, Chairez C, McManus M, Nettles MJ, Zemanick K, Morse CG, Benator D, Kovacs JA, Hadigan C. Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Res Hum Retroviruses. 2015 Oct;31(10):961-6. doi: 10.1089/AID.2015.0093. Epub 2015 Aug 24.</citation>
    <PMID>26214341</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <results_first_submitted>April 10, 2014</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2014</results_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Fatty Liver</keyword>
  <keyword>Steatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Decision will be made at the time of request</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg daily for 48 weeks&#xD;
Pioglitazone</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo once daily for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg daily for 48 weeks&#xD;
Pioglitazone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo once daily for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="5"/>
                    <measurement group_id="B2" value="53" spread="6"/>
                    <measurement group_id="B3" value="52" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.</title>
        <description>Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline</description>
        <time_frame>48 weeks</time_frame>
        <population>Two subjects (one in each group) did not have a follow up MRI for comparision to baseline. One developed claustrophobia and could not tolerate MRI and one was discontinued from study due to other illnesses.</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone 45 mg daily for 48 weeks&#xD;
Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hepatic Steatosis and Hepatic Inflammation/Fibrosis in HIV/HCV Co-infected Patients With Steatosis.</title>
          <description>Change in hepatic steatosis and hepatic inflammation/fibrosis in HIV/HCV co-infected patients with steatosis. Change in Hepatic Fat Content measured by MR spectroscopy: 48 weeks compared to Baseline</description>
          <population>Two subjects (one in each group) did not have a follow up MRI for comparision to baseline. One developed claustrophobia and could not tolerate MRI and one was discontinued from study due to other illnesses.</population>
          <units>percentage of hepatic fat on MRS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" spread="4.6"/>
                    <measurement group_id="O2" value="-2.17" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo</title>
        <description>Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values</description>
        <time_frame>48 weeks</time_frame>
        <population>One subject in the placebo arm was discontinued due to health issues and does not have a 48 week OGTT available</population>
        <group_list>
          <group group_id="O1">
            <title>Pioglitazone</title>
            <description>pioglitazone 45 mg daily for 48 weeks&#xD;
Pioglitazone</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo once daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Resistance in HIV- and HCV-infected Patients With Steatosis Compared to Placebo</title>
          <description>Change in Glucose Area Under the Curve from standard oral glucose challenge ( baseline to 2 hours): Week 48 - Baseline values</description>
          <population>One subject in the placebo arm was discontinued due to health issues and does not have a 48 week OGTT available</population>
          <units>mg*120 minutes/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31" spread="29.2"/>
                    <measurement group_id="O2" value="11" spread="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks of randomized study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>pioglitazone 45 mg daily for 48 weeks&#xD;
Pioglitazone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo once daily for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Protocol Tox Table</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dental Abscess</sub_title>
                <description>Dental abscess requiring treatment related to poor dentition</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Cancer</sub_title>
                <description>Patient was diagnosed with advanced stage lung cancer during study participation. Participation in the study was discontinued by the study team when the diagnosis was made.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <description>Renal insufficiency identified, related to HIV antiretroviral therapy. Resolved after changing antiretroviral mediactions</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Protocol Tox Table</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Increased cholesterol</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Decrease serum albumin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study failed to enroll to the originally established sample size due to slow enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Colleen Hadigan MD MPH</name_or_title>
      <organization>NIAID</organization>
      <phone>301-594-5754</phone>
      <email>hadiganc@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

